Syndax Pharmaceuticals, Inc.
SNDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,131,923 | $1,518,211 | $1,546,365 | $1,139,699 |
| - Cash | $154,083 | $295,394 | $74,356 | $221,965 |
| + Debt | $345,739 | $1,635 | $1,161 | $20,967 |
| Enterprise Value | $1,323,579 | $1,224,452 | $1,473,170 | $938,701 |
| Revenue | $23,680 | $0 | $0 | $139,709 |
| % Growth | – | – | -100% | – |
| Gross Profit | $22,854 | $0 | $0 | $139,709 |
| % Margin | 96.5% | – | – | 100% |
| EBITDA | -$313,821 | -$209,140 | -$146,168 | $26,868 |
| % Margin | -1,325.3% | – | – | 19.2% |
| Net Income | -$318,758 | -$209,360 | -$149,338 | $24,926 |
| % Margin | -1,346.1% | – | – | 17.8% |
| EPS Diluted | -3.73 | -2.98 | -2.46 | 0.48 |
| % Growth | -25.2% | -21.1% | -612.5% | – |
| Operating Cash Flow | -$274,903 | -$160,601 | -$133,675 | $29,131 |
| Capital Expenditures | $0 | $0 | -$225 | -$129 |
| Free Cash Flow | -$274,903 | -$160,601 | -$133,900 | $29,002 |